FDA postpones decision on Intercept's lead liver drug

December 17, 2015 10:19 PM

19 0

FDA postpones decision on Intercept's lead liver drug

The U.S. Food and Drug Administration has postponed by three months its decision on Intercept Pharmaceuticals Inc's marketing application for its lead drug, to treat a kind of liver disease.

The company's shares fell 7.2 percent to $154 in extended trading on Thursday.

Read more

To category page

Loading...